Company intelligence / Profile preview
Bryan & Company
- Ownership
- Private
- Development stage
- Other
01
Overview
Bryan Therapeutics focuses on developing drugs that restore or generate nitric oxide in the human body. Their lead programs include a topical wound care product and an orally disintegrating lozenge targeting cardiovascular diseases and COVID‑19. The company leverages Dr. Nathan S. Bryan’s research and patents around nitric oxide biology. Some products are moving toward clinical trials or regulatory fast track status.[1]
- Therapeutic areas
- DermatologyCardiovascularInfectious Diseases
- Modalities
- Small moleculeTopical therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Bryan & Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bryan & Company.